Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma

Abstract

Tumor-driven immune suppression is a major barrier to successful immunotherapy in ovarian carcinomas (OvCa). Among various mechanisms responsible for immune suppression, arginase-1 (ARG1)-carrying small extracellular vesicles (EVs) emerge as important contributors to tumor growth and tumor escape from the host immune system. Here, we report that small EVs found in the ascites and plasma of OvCa patients contain ARG1. EVs suppress proliferation of CD4 + and CD8 + T-cells in vitro and in vivo in OvCa mouse models. In mice, ARG1-containing EVs are transported to draining lymph nodes, taken up by dendritic cells and inhibit antigen-specific T-cell proliferation. Increased expression of ARG1 in mouse OvCa cells is associated with accelerated tumor progression that can be blocked by an arginase inhibitor. Altogether, our studies show that tumor cells use EVs as vehicles to carry over long distances and deliver to immune cells a metabolic checkpoint molecule – ARG1, mitigating anti-tumor immune responses.

References 66

1. 1.

   Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int. J. Cancer. 2017;140:2451-2460.

   Not in our library10.1002/ijc.30676

2. 2.

   Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann. Oncol. 2016;27:114-121.

   Not in our library10.1093/annonc/mdv500

3. 3.

   International Collaborative Ovarian Neoplasm, G. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet360, 505–515 (2002).

   Not in our library10.1016/s0140-6736(02)09738-6

4. 4.

   Hung CF, Wu TC, Monie A, Roden R. Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol. Rev. 2008;222:43-69.

   Not in our library10.1111/j.1600-065x.2008.00622.x

5. 5.

   Alipour S, et al. Specific immunotherapy in ovarian cancer: a systematic review. Immunotherapy. 2016;8:1193-1204.

   Not in our library10.2217/imt-2016-0034

6. 6.

   Mittica G, et al. Adoptive immunotherapy against ovarian cancer. J. Ovarian Res. 2016;9:30.

   Not in our library10.1186/s13048-016-0236-9

7. 7.

   Kandalaft LE, Motz GT, Duraiswamy J, Coukos G. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastas. Rev. 2011;30:141-151.

   Not in our library10.1007/s10555-011-9289-9

8. 8.

   Whiteside TL. Tricks tumors use to escape from immune control. Oral Oncol. 2009;45:e119-e123.

   Not in our library10.1016/j.oraloncology.2009.03.006

9. 9.

   Han LY, et al. HLA class I antigen processing machinery component expression and intratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin. Cancer Res. 2008;14:3372-3379.

   Not in our library10.1158/1078-0432.ccr-07-4433

10. 10.

    Dietl J, Engel JB, Wischhusen J. The role of regulatory T cells in ovarian cancer. Int. J. Gynecol. Cancer. 2007;17:764-770.

    Not in our library10.1111/j.1525-1438.2006.00861.x

11. 11.

    Kryczek I, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 2006;203:871-881.

    Not in our library10.1084/jem.20050930

12. 12.

    Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol. Oncol. 2010;117:366-372.

    Not in our library10.1016/j.ygyno.2010.01.019

13. 13.

    Maj T, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat. Immunol. 2017;18:1332-1341.

    Not in our library10.1038/ni.3868

14. 14.

    Singer K, Gottfried E, Kreutz M, Mackensen A. Suppression of T-cell responses by tumor metabolites. Cancer Immunol. Immunother. 2011;60:425-431.

    Not in our library10.1007/s00262-010-0967-1

15. 15.

    Rodriguez PC, et al. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J. Biol. Chem. 2002;277:21123-21129.

    Not in our library10.1074/jbc.m110675200

16. 16.

    Rodriguez PC, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64:5839-5849.

    Not in our library10.1158/0008-5472.can-04-0465

17. 17.

    Van de Velde LA, et al. T cells encountering myeloid cells programmed for amino acid-dependent immunosuppression use Rictor/mTORC2 protein for proliferative checkpoint decisions. J. Biol. Chem. 2017;292:15-30.

    Not in our library10.1074/jbc.m116.766238

18. 18.

    Modolell M, et al. Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis. PLoS Negl. Trop. Dis. 2009;3:e480.

    Not in our library10.1371/journal.pntd.0000480

19. 19.

    Narita Y, et al. The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice. J. Immunol. 2013;190:812-820.

    Not in our library10.4049/jimmunol.1103797

20. 20.

    Munder M. Arginase: an emerging key player in the mammalian immune system. Br. J. Pharm. 2009;158:638-651.

    Not in our library10.1111/j.1476-5381.2009.00291.x

21. 21.

    de Boniface J, Mao Y, Schmidt-Mende J, Kiessling R, Poschke I. Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients. Oncoimmunology. 2012;1:1305-1312.

    Not in our library10.4161/onci.21678

22. 22.

    Suer Gokmen S, Yoruk Y, Cakir E, Yorulmaz F, Gulen S. Arginase and ornithine, as markers in human non-small cell lung carcinoma. Cancer Biochem. Biophys. 1999;17:125-131.

    Not in our library

23. 23.

    Bron L, et al. Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. Int. J. Cancer. 2013;132:E85-E93.

    Not in our library10.1002/ijc.27728

24. 24.

    Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 2007;13:721s-726s.

    Not in our library10.1158/1078-0432.ccr-06-2197

25. 25.

    Grabon W, Mielczarek-Puta M, Chrzanowska A, Baranczyk-Kuzma A. l-arginine as a factor increasing arginase significance in diagnosis of primary and metastatic colorectal cancer. Clin. Biochem. 2009;42:353-357.

    Not in our library10.1016/j.clinbiochem.2008.11.018

26. 26.

    Gokmen SS, Aygit AC, Ayhan MS, Yorulmaz F, Gulen S. Significance of arginase and ornithine in malignant tumors of the human skin. J. Lab. Clin. Med. 2001;137:340-344.

    Not in our library10.1067/mlc.2001.114543

27. 27.

    Bedoya AM, et al. Immunosuppression in cervical cancer with special reference to arginase activity. Gynecol. Oncol. 2014;135:74-80.

    Not in our library10.1016/j.ygyno.2014.07.096

28. 28.

    Raber P, Ochoa AC, Rodriguez PC. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol. Invest. 2012;41:614-634.

    Not in our library10.3109/08820139.2012.680634

29. 29.

    Gannon PO, et al. Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer. PLoS One. 2010;5:e12107.

    Not in our library10.1371/journal.pone.0012107

30. 30.

    Mussai F, et al. Neuroblastoma arginase activity creates an immunosuppressive microenvironment that impairs autologous and engineered immunity. Cancer Res. 2015;75:3043-3053.

    Not in our library10.1158/0008-5472.can-14-3443

31. 31.

    Mussai F, et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood. 2013;122:749-758.

    Not in our library10.1182/blood-2013-01-480129

32. 32.

    Shenoy GN, et al. Exosomes associated with human ovarian tumors harbor a reversible checkpoint of T-cell responses. Cancer Immunol. Res. 2018;6:236-247.

    Not in our library10.1158/2326-6066.cir-17-0113

33. 33.

    Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin. Cancer Res. 2003;9:5113-5119.

    Not in our library

34. 34.

    Lea, J. et al. Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof of concept study. Oncotarget8, 14395–14407 (2017).

    Not in our library10.18632/oncotarget.14795

35. 35.

    Whiteside TL. Exosomes in cancer: another mechanism of tumor-induced immune suppression. Adv. Exp. Med. Biol. 2017;1036:81-89.

    Not in our library10.1007/978-3-319-67577-0_6

36. 36.

    Kowal J, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc. Natl Acad. Sci. USA. 2016;113:E968-E977.

    Not in our library10.1073/pnas.1521230113

37. 37.

    Stanczak, P. S. et al. Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy. Ann. Oncol.28, 1180P (2017) 10.1093/annonc/mdx376.045.

    Not in our library

38. 38.
    Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy · 2018

    No notice
39. 39.
    Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment · 2017

    No notice
40. 40.

    Bak SP, Alonso A, Turk MJ, Berwin B. Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol. Immunol. 2008;46:258-268.

    Not in our library10.1016/j.molimm.2008.08.266

Cited by papers we hold 16

• Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets · 2025
  No notice
• Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy · 2024
  No notice
• Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy · 2023
  No notice
• Engineered exosomes from different sources for cancer-targeted therapy · 2023
  No notice
• Dendritic cell subsets in cancer immunity and tumor antigen sensing · 2023
  No notice
• Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway · 2022
  Not checked
• GM-CSF: A Double-Edged Sword in Cancer Immunotherapy · 2022
  No notice
• Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion · 2022
  No notice
• Glioma-Derived Extracellular Vesicles – Far More Than Local Mediators · 2021
  Not checked
• Metabolism of Amino Acids in Cancer · 2021
  No notice
• The Role of Macrophages in Cancer Development and Therapy · 2021
  No notice
• Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker · 2020
  No notice
• Mechanisms of T-Cell Exhaustion in Pancreatic Cancer · 2020
  No notice
• The Role of Extracellular Vesicles in the Hallmarks of Cancer and Drug Resistance · 2020
  No notice
• Myeloid Cell-Derived Arginase in Cancer Immune Response · 2020
  No notice
• Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3 · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.